Non-coding RNA company Twentyeight-Seven debuts with $65M

Twentyeight-Seven Therapeutics Inc. (Cambridge, Mass.) raised $65 million in a series A co-led by MPM Capital and Novartis Venture Fund. Johnson & Johnson Innovation-JJDC Inc., Vertex Ventures HC,

Read the full 281 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE